A phase Ib/II TBCRC032 study has investigated the safety and effectiveness of the androgen receptor antagonist enzalutamide in combination with the PI3K inhibitor taselisib in patients with metastatic AR‐positive (≥10%) breast cancer, including TNBC. Here, PIK3CA is linked to breast cancer.